https://www.selleckchem.com/peptide/avexitide.html
The MESV construct was non-allergenic, stable, and highly antigenic. Molecular docking showed a stable and high binding affinity of MESV with human pathogenic toll-like receptors-3 (TLR3). Furthermore, in silico immune simulation revealed significant immunogenic response of MESV. Finally, MEV codons were optimized for its in silico cloning into the Escherichia coli K-12 system, to ensure its increased expression. The MESV developed in this study is capable of generating immune response against COVID-19. Therefore, if designed MESV furt
Like
Comment
Share
